Companies › Parvus Therapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Immunology; next expected readout Nov 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PVT401 pMHC-peptide nanomedicine: iron oxide nanoparticle core surrounded by dextran linked to mu | HLA-DR | Phase 1 | Inflammatory Bowel Disease (IBD) | Nov 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07423000 | PVT401 | Phase 1 | Inflammatory Bowel Disease (IBD) | Immunology | Nov 2027 |
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.